AHA 2019 Pre-procedural administration of colchicine vs. placebo did not reduce PCI-related myocardial injury or MACE at 30 days, but attenuated increase in IL-6 and hsCRP at 24 hours post-PCI.
Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.
A post-hoc analysis of the GLOBAL LEADERS trial in patient undergoing multivessel PCI showed that ticagrelor monotherapy reduced all-cause death or MI, without any difference in bleeding compared to standard DAPT regimen.
CSI Paris Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.
CSI Paris Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.
A meta-analysis of RE-DUAL PCI, PIONEER AF-PCI and AUGUSTUS compared NOAC- and VKA-based regimens and antithrombotic therapies with and without aspirin for ischemic outcomes and CV and total mortality.
Starting evolocumab treatment on top of high-intensity statin, in the hospital soon after ACS, safely and effectively lowers LDL-c to below guideline-recommended levels for almost all.
ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.
ESC 2019 Based on data of the COMPLETE trial, prof. Mehta answers the questions whether routine complete revascularization vs. culprit lesion only PCI can change cardiac outcomes and disease course, and whether it should become standard practice for patients with STEMI.
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.
ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.
ESC 2019 Prof. Stewart investigated two protocols for oxygen administration in 40,000 patients with ischemic symptoms in New-Zealand. In most, oxygen gives no advantages and no disadvantages, but a subgroup may benefit from oxygen.